RxDoctor Payments Data

Angelena Lopez, MD

Pulmonary Disease · West Hollywood, CANPI 1073926275

Payments from drug & device makers

What this record shows

This record is dominated by education: $2,580 of the $2,806 with a category attached, or 92.0%. Intuitive Surgical accounts for 89.3% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $2,584, more than ten times the $5 reported in 2021.

$2,806in general payments, 2019–2025

Across 10 payments — averaging $280.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$3K
  • Actelion Pharmaceuticals US, Inc.$139
  • Coaptech, Inc.$76
  • Pulmonx Corporation$61
  • Boston Scientific$24

What the payments were for

  • Food & beverage$2268%
  • Education$2,58092%

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Intuitive Surgical2$2,505
Actelion Pharmaceuticals US, Inc.3$139
Coaptech, Inc.3$76
Pulmonx Corporation1$61
Boston Scientific1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,806 in reported general payments places this provider in the 60th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Medicare billing

Part B allowed, 2024
$124,256
Medicare patients
326
Services billed
797

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban37$37,077
Wixela InhubFluticasone Propion/Salmeterol11$1,622

Paid to pharmacies, not to this prescriber.

Other pulmonary disease in West Hollywood

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →